Please select the option that best describes you:
What factors drive you to prioritize treatments that inhibit T cells vs B cell depletion when choosing therapies for patients with refractory SLE?
This question is part of a collaboration with RheumMadness and is specifically in reference to: Teclistamab-Induced Remission in Refractory Systemic Lupus Erythematosus